News & Events

Dispatch of Annual Report and Shareholder Circular

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to…

Final Results for the year ended 30 June 2018

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the…

Contract award

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k…

Physiomics expands technical team

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full.

Trading update

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm…

Dr Orrell to present at ISF conference

Physiomics consultant and senior advisor, Dr David Orrell, will give one of the keynote speeches at the 38th International Symposium on Forecasting, Colorado USA on 17th…

Physiomics launches updated website

Physiomics is pleased to announce that following feedback from clients and shareholders it has today updated its website at http://www.physiomics-plc.com/.  In its recent placing…

Placing

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to watch video.